Literature DB >> 30723183

The effect of radiographic emphysema in assessing lung cancer risk.

Patrick C Yong1, Keith Sigel1, Juan Pablo de-Torres2,3, Grace Mhango1, Minal Kale1, Chung Yin Kong4, Javier J Zulueta5, David Wilson6, Stacey-Ann Whittaker Brown1, Christopher Slatore7,8, Juan Wisnivesky1.   

Abstract

PURPOSE: Lung cancer risk models optimise screening by identifying subjects at highest risk, but none of them consider emphysema, a risk factor identifiable on baseline screen. Subjects with a negative baseline low-dose CT (LDCT) screen are at lower risk for subsequent diagnosis and may benefit from risk stratification prior to additional screening, thus we investigated the role of radiographic emphysema as an additional predictor of lung cancer diagnosis in participants with negative baseline LDCT screens of the National Lung Screening Trial.
METHODS: Our cohorts consist of participants with a negative baseline (T0) LDCT screen (n=16 624) and participants who subsequently had a negative 1-year follow-up (T1) screen (n=14 530). Lung cancer risk scores were calculated using the Bach, PLCOm2012 and Liverpool Lung Project models. Risk of incident lung cancer diagnosis at the end of the study and number screened per incident lung cancer were compared between participants with and without radiographic emphysema.
RESULTS: Radiographic emphysema was independently associated with nearly double the hazard of lung cancer diagnosis at both the second (T1) and third (T2) annual LDCT in all three risk models (HR range 1.9-2.0, p<0.001 for all comparisons). The number screened per incident lung cancer was considerably lower in participants with radiographic emphysema (62 vs 28 at T1 and 91 vs 40 at T2).
CONCLUSION: Radiographic emphysema is an independent predictor of lung cancer diagnosis and may help guide decisions surrounding further screening for eligible patients. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  emphysema; lung cancer; national lung screening trial; risk assessment; screening

Mesh:

Year:  2019        PMID: 30723183     DOI: 10.1136/thoraxjnl-2018-212457

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  6 in total

1.  Lung cancer screening: how do we make it better?

Authors:  David O Wilson; Juan Pablo de Torres
Journal:  Quant Imaging Med Surg       Date:  2020-02

2.  Emphysema assessment for personalized immunotherapy response prediction in lung cancer patients.

Authors:  Dimitra Kerdidani; Sophia Magkouta; Maria Tsoumakidou
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

3.  Quantitative Emphysema on Low-Dose CT Imaging of the Chest and Risk of Lung Cancer and Airflow Obstruction: An Analysis of the National Lung Screening Trial.

Authors:  Wassim W Labaki; Meng Xia; Susan Murray; Charles R Hatt; Abdullah Al-Abcha; Michael C Ferrera; Catherine A Meldrum; Lauren A Keith; Craig J Galbán; Douglas A Arenberg; Jeffrey L Curtis; Fernando J Martinez; Ella A Kazerooni; MeiLan K Han
Journal:  Chest       Date:  2020-12-14       Impact factor: 9.410

4.  The clinical relevance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in chronic obstructive pulmonary disease with lung cancer.

Authors:  Aiping Ma; Guangdong Wang; Yan Du; Weixi Guo; Jiaxi Guo; Yi Hu; Dongyu Bai; Huiping Huang; Lianjin Zhuang; Jinhan Chen; Qun Liu
Journal:  Front Oncol       Date:  2022-09-27       Impact factor: 5.738

5.  Deep Learning Using Chest Radiographs to Identify High-Risk Smokers for Lung Cancer Screening Computed Tomography: Development and Validation of a Prediction Model.

Authors:  Michael T Lu; Vineet K Raghu; Thomas Mayrhofer; Hugo J W L Aerts; Udo Hoffmann
Journal:  Ann Intern Med       Date:  2020-09-01       Impact factor: 51.598

6.  Immune Cell Subtypes and Cytokines in Lung Tumor Microenvironment: Influence of COPD.

Authors:  Jun Tang; Daniel Ramis-Cabrer; Víctor Curull; Xuejie Wang; Liyun Qin; Mercé Mateu-Jiménez; Xavier Duran; Lara Pijuan; Alberto Rodríguez-Fuster; Rafael Aguiló Espases; Esther Barreiro
Journal:  Cancers (Basel)       Date:  2020-05-13       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.